Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Johnson and Johnson
Chinese Patent Office
Chubb
Cerilliant
UBS
McKinsey
Harvard Business School
Daiichi Sankyo
Cipla

Generated: October 18, 2017

DrugPatentWatch Database Preview

Valeant Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT, and when can generic versions of VALEANT drugs launch?

VALEANT has one hundred and twenty-five approved drugs.

There are forty-seven US patents protecting VALEANT drugs.

There are eight hundred and two patent family members on VALEANT drugs in fifty-five countries and sixty-four supplementary protection certificates in twelve countries.

Summary for Applicant: Valeant

International Patents:802
US Patents:47
Tradenames:102
Ingredients:80
NDAs:125
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl
PERMAX
pergolide mesylate
TABLET;ORAL019385-003Dec 30, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms Intl
UCERIS
budesonide
TABLET, EXTENDED RELEASE;ORAL203634-001Jan 14, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharms North
NIFEDIPINE
nifedipine
TABLET, EXTENDED RELEASE;ORAL076070-001Aug 16, 2002AB1RXNoNo► Subscribe► Subscribe► Subscribe
Valeant Intl
CARDIZEM LA
diltiazem hydrochloride
TABLET, EXTENDED RELEASE;ORAL021392-003Feb 6, 2003ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Valeant Pharms North
APLENZIN
bupropion hydrobromide
TABLET, EXTENDED RELEASE;ORAL022108-002Apr 23, 2008RXYesNo► Subscribe► SubscribeY ► Subscribe
Valeant Pharms Intl
APRISO
mesalamine
CAPSULE, EXTENDED RELEASE;ORAL022301-001Oct 31, 2008RXYesYes► Subscribe► SubscribeY ► Subscribe
Valeant Pharm Intl
DIPHENHYDRAMINE HYDROCHLORIDE
diphenhydramine hydrochloride
CAPSULE;ORAL080592-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-001Nov 4, 1993ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Intl
RETIN-A
tretinoin
GEL;TOPICAL017955-001Approved Prior to Jan 1, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756-001Dec 17, 2004RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Valeant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North
IPRIVASK
desirudin recombinant
INJECTABLE;SUBCUTANEOUS021271-001Apr 4, 2003► Subscribe► Subscribe
Valeant Pharms
ULTRAM ER
tramadol hydrochloride
TABLET, EXTENDED RELEASE;ORAL021692-002Sep 8, 2005► Subscribe► Subscribe
Valeant Intl
CARDIZEM CD
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020062-005Aug 24, 1999► Subscribe► Subscribe
Valeant Pharms North
DIASTAT
diazepam
GEL;RECTAL020648-002Jul 29, 1997► Subscribe► Subscribe
Valeant Pharms North
VASOTEC
enalapril maleate
TABLET;ORAL018998-001Dec 24, 1985► Subscribe► Subscribe
Valeant Intl
RETIN-A
tretinoin
SOLUTION;TOPICAL016921-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Valeant Pharms Llc
TIMOPTIC-XE
timolol maleate
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC020330-001Nov 4, 1993► Subscribe► Subscribe
Valeant Intl
CARDIZEM CD
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020062-004Dec 27, 1991► Subscribe► Subscribe
Valeant Bermuda
ELIDEL
pimecrolimus
CREAM;TOPICAL021302-001Dec 13, 2001► Subscribe► Subscribe
Valeant Pharms North
IPRIVASK
desirudin recombinant
INJECTABLE;SUBCUTANEOUS021271-001Apr 4, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for VALEANT drugs

Drugname Dosage Strength Tradename Submissiondate
ribavirin
For Inhalation Solution6 gm/vial
VIRAZOLE
5/22/2014
balsalazide disodium
Tablets1.1 g
GIAZO
11/5/2013
budesonide
Extended-release Tablets9 mg
UCERIS
3/11/2013
mesalamine
Extended-release Capsules0.375 g
APRISO
4/3/2012
fluorouracil
Cream0.5%
CARAC
7/29/2011
bexarotene
Capsules75 mg
TARGRETIN
6/6/2011
tretinoin
Gel0.04%
RETIN-A MICRO
12/20/2010
tretinoin
Gel0.1%
RETIN-A MICRO
7/8/2010
bupropion hydrobromide
Extended-release Tablets522 mg
APLENZIN
12/24/2009
bupropion hydrobromide
Extended-release Tablets174 mg
APLENZIN
9/28/2009
bupropion hydrobromide
Extended-release Tablets348 mg
APLENZIN
9/24/2009
diazepam
Rectal Gel5 mg/mL, 2mL pre-filled syringe
DIASTAT ACUDIAL
12/23/2008
diazepam
Rectal Gel5 mg/mL, 4mL pre-filled syringe
DIASTAT ACUDIAL
12/8/2008
tramadol hydrochloride
Extended-release Tablets300 mg
ULTRAM ER
9/25/2007
tramadol hydrochloride
Extended-release Tablets200 mg
ULTRAM ER
3/28/2007
tramadol hydrochloride
Extended-release Tablets100 mg
ULTRAM ER
1/8/2007
diltiazem hydrochloride
Extended-release Tablets120 mg, 180 mg, 240 mg, 300 mg and 360 mg
CARDIZEM LA
8/30/2005
diltiazem hydrochloride
Extended-release Tablets420 mg
CARDIZEM LA
4/25/2005
bupropion hydrochloride
Extended-release Tablets150 mg and 300 mg
WELLBUTRIN XL
9/21/2004
diazepam
Rectal Gel2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL
DIASTAT
3/23/2004

Premature patent expirations for VALEANT

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Valeant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,176,295Systematic evolution of ligands by exponential enrichment: blended SELEX► Subscribe
5,763,177 Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex► Subscribe
5,637,459 Systematic evolution of ligands by exponential enrichment: chimeric selex► Subscribe
6,143,327 Delayed release coated tablet of bupropion hydrochloride► Subscribe
5,858,660 Parallel selex► Subscribe
5,753,494 Method and apparatus for treating contaminated soils with ozone► Subscribe
5,145,675 Two step method for preparation of controlled release formulations► Subscribe
6,300,074 Systematic evolution of ligands by exponential enrichment: Chemi-SELEX► Subscribe
5,849,890 High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones► Subscribe
6,759,392 High affinity RNA ligands of basic fibroblast growth factor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Valeant Drugs

Country Document Number Estimated Expiration
Australia2004210606► Subscribe
Australia6748700► Subscribe
Argentina016597► Subscribe
European Patent Office1695978► Subscribe
Denmark0678086► Subscribe
Australia783347► Subscribe
JapanH08252100► Subscribe
Germany69638318► Subscribe
Israel137391► Subscribe
Australia5670796► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Valeant Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2001Austria► SubscribePRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
C/GB04/012United Kingdom► SubscribePRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
13/055Ireland► SubscribePRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT, PRECURSOR OR DERIVATIVE THEREOF, E.G. QUINIDINE SULPHATE AND IN PARTICULAR QUINIDINE SULPHATE DIHYDRATE, PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/13/833 20130624
0957929/01Switzerland► SubscribePRODUCT NAME: PEGAPTANIB; REGISTRATION NUMBER/DATE: SWISSMEDIC 57459 15.02.2006
2006004,C0957929Lithuania► SubscribePRODUCT NAME: PEGAPTANIBUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
/2000Austria► SubscribePRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201
90049-3Sweden► SubscribePRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
20/2006Austria► SubscribePRODUCT NAME: PEGAPTANIB UND SALZE DAVON
C0112Belgium► SubscribePRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 19970827
C/GB11/054United Kingdom► SubscribePRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
McKesson
Moodys
Cantor Fitzgerald
Cerilliant
Queensland Health
Mallinckrodt
Federal Trade Commission
Healthtrust
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot